Aktis Oncology (NASDAQ:AKTS) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Aktis Oncology (NASDAQ:AKTS) posted its quarterly earnings results on Thursday. The technology company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.07), FiscalAI reports. The firm had revenue of $3.91 million for the quarter, compared to analyst estimates of $4.02 million.

Aktis Oncology Stock Performance

Shares of NASDAQ:AKTS traded down $0.77 during trading hours on Thursday, hitting $16.27. The stock had a trading volume of 134,918 shares, compared to its average volume of 354,245. The stock’s fifty day simple moving average is $18.96 and its 200 day simple moving average is $20.84. The firm has a market capitalization of $874.46 million and a price-to-earnings ratio of -19.84. Aktis Oncology has a 1-year low of $13.96 and a 1-year high of $34.19.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Oppenheimer assumed coverage on Aktis Oncology in a report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 target price for the company. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Wedbush reiterated an “outperform” rating and set a $35.00 price target on shares of Aktis Oncology in a research report on Friday, October 2nd. BMO Capital Markets started coverage on Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. Finally, Weiss Ratings lowered Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.62.

Aktis Oncology Company Profile

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.